Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutics, Inc. - Common Stock
(NQ:
SAGE
)
7.140
-0.040 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...
Via
Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 01, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 2, 2021
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
Analyst Ratings For Sage Therapeutics
October 12, 2021
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings...
Via
Benzinga
Sage Therapeutics to Host Sage FutureCast Webcast
November 29, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 24, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
November 11, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
November 08, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) ...
Via
Benzinga
What 8 Analyst Ratings Have To Say About Sage Therapeutics
November 03, 2021
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings ...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
November 03, 2021
Needham boosted Paycom Software, Inc. (NYSE:PAYC) ...
Via
Benzinga
Sage Therapeutics Inc (SAGE) Q3 2021 Earnings Call Transcript
November 02, 2021
SAGE earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed
November 02, 2021
Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a...
Via
Benzinga
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
November 02, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Preview: Sage Therapeutics's Earnings
November 01, 2021
Sage Therapeutics (NASDAQ:SAGE) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
B. Riley Sees 'Significant Potential' In This Beaten-Up Biotech Stock
October 21, 2021
B. Riley analyst calls Seelos Therapeutics Inc (NASDAQ:
Via
Benzinga
Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 20, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
What 7 Analyst Ratings Have To Say About Sage Therapeutics
October 20, 2021
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings...
Via
Benzinga
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
October 20, 2021
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
October 20, 2021
Mizuho cut QUALCOMM Incorporated (NASDAQ: QCOM) price target from $180 to $165. QUALCOMM shares fell 0.3% to $132.13 in pre-market trading. Deutsche Bank raised the price...
Via
Benzinga
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
October 19, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
October 18, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Rising Oil Prices and Yields Makes Market Navigation More Complex
October 05, 2021
Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise...
Via
Benzinga
Exposures
Fossil Fuels
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
October 04, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Launches SageCitizen Social Impact Initiative
October 01, 2021
From
Sage Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.